CTX131

Cell therapy

DiscontinuedCD70
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-11-10), as a strategic decision by the sponsor

CRISPR Therapeutics redirected resources away from CTX131 (Q3 2025 results). The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT06492304 · T Cell Lymphoma · Phase 1 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (2)
Other / comorbidity
NCT06492304 · CRISPR Therapeutics
2024-08-13 – 2026-03-11 · T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Clear Cell Renal Cell Carcinoma: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CTX131: this drugDiscontinuedCell therapyCD70not yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signalNo reviewed efficacy summary in this indication
CasdatifanPhase 3Small moleculeHIF-2alphanot yet gradedNo reviewed efficacy summary in this indication
Cusatuzumab
Phase 2(overall)
Monoclonal antibodyCD70
Weak signal(overall)
No reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
DarlifarnibPhase 1Small moleculeFarnesyltransferasenot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
XmAb819Phase 1Multispecific antibodyENPP3 x CD3not yet gradedNo reviewed efficacy summary in this indication
PF-08046040
—(overall)
UndisclosedCD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70, CD70
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.